Source Fact: Financial Supervisory Service DART / 2024-09-13
Disclosure Type: Conclusion of Single Sales/Supply Contract
💡 3-Second Summary
Samsung Biologics has officially disclosed a contract manufacturing organization (CMO) agreement worth approximately KRW 119.1B (USD 88.92M) with an Asian-based pharmaceutical company, following an upward revision of a 2023 contract that has now crossed the regulatory disclosure threshold.
📊 1. [Summary of Core Disclosure & Key Figures]
- Contract Name: Contract Manufacturing Agreement (Pharmaceuticals)
- Contract Amount: KRW 119,112,745,680 (Fixed amount: USD 88,916,651)
- Applied FX Rate: KRW 1,339.60 per USD (Based on the initial standard proxy rate on September 13, 2024)
- Ratio to Recent Sales: 3.22% of the 2023 consolidated annual revenue (KRW 3.69T)
- Counterparty: A pharmaceutical company located in Asia (Identity remaining confidential until December 31, 2028, due to trade secrecy)
- Contract Period: June 2, 2023 ~ December 31, 2028
- Execution (Order) Date: September 13, 2024
- Special Note: This contract was initially exempt from public disclosure upon its inception on June 2, 2023, due to falling short of the mandatory regulatory value threshold. However, following an amendment that expanded the deal’s scale, it has newly triggered the legal disclosure requirements.
📈 2. [Expert Insight: Implications for Investors]
- Evidence of Contract Expansion: Shifting from an undisclosed baseline to a mandatory public filing indicates an incremental expansion in order volume or heightened client demand. This serves as a healthy indicator that could potentially exert a positive impact on strengthening the firm’s backlog Fundamental.
- Securing Mid-Term Production Visibility: Securing a continuous manufacturing runway through late 2028 offers visible backlog stability. This could likely assist in insulating utility risks and maintaining robust asset utilization metrics across active production lines over the next four years.
- Investor Consideration: Because the contract value is fixed in USD (approx. USD 88.92M), the realized revenue denominated in KRW may undergo unexpected fluctuations based on exchange rate trends at the time of future invoicing. Furthermore, as specific operational and client attributes remain masked under strict confidentiality clauses until late 2028, market participants must factor in this information asymmetry.
📝 Editor’s Comment (by K-STOCK Editor)
The core operational takeaway from this filing is the transition of a legacy un-disclosed contract into a public milestone via an upward amendment. It highlights a scenario where an initial smaller order placed in 2023 has successfully scaled up due to growing client requirements, hitting the regulatory threshold. While the revenue ratio of 3.22% is a modest addition to the current top-line structure, it underscores expanding regional roots in Asia and an effective client lock-in mechanism. Securing a steady production horizon out through 2028 reaffirms that the quality and operational continuity of Samsung Biologics’ order book remains entirely intact.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
